01—Abstract
Summary
Summary of the 8-K filed August 7, 2025. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated (Nasdaq: INSM) reported second-quarter 2025 results on August 7, 2025, with total ARIKAYCE revenue of $107.4 milliona, up 18.9% from $90.3 million in the second quarter of 2024.
Growth was seen across all regions, with U.S. revenue at $68.7 millionb (up 7.7%), Japan at $30.7 million (up 45.3%), and Europe & Rest of World at $8.1 million (up 48.3%). The company reported a net loss of $321.7 million, or $1.70 per share, compared with a net loss of $300.6 million, or $1.94 per share, a year earlier. Operating expenses rose, with R&D at $177.2 million and SG&A at $154.8 million, the latter driven by headcount growth and commercial readiness activities for brensocatib.
The key near-term catalyst is the PDUFA target action date of August 12, 2025, for brensocatib in bronchiectasis, with Insmed stating it expects an immediate U.S. launch if approved. The company also reiterated its 2025 global ARIKAYCE revenue guidance of $405 million to $425 millionc. On the pipeline, Insmed reported positive Phase 2b topline data for TPIP in PAH in June 2025, with a Phase 3 study in PH-ILD planned for the second half of 2025 and in PAH for early 2026.
Topline data from the Phase 2b BiRCh study of brensocatib in CRSsNP is expected by the end of 2025. As of June 30, 2025, cash, cash equivalents, and marketable securities totaled approximately $1.9 billiond, following an June 2025 equity offering with estimated net proceeds of $823.1 million.
The company also redeemed its remaining $569.5 million of 0.75% convertible notes due 2028 in April 2025. Shareholders' equity rose to $1.25 billion at June 30, 2025, from $285.4 million at December 31, 2024.
02—Key points
Key Highlights
- Total Q2 2025 revenue of $107.4 million, up 18.9% year over year, with growth in all geographic regions
- Net loss widened to $321.7 million ($1.70 per share) from $300.6 million ($1.94 per share) in Q2 2024
- Brensocatib NDA for bronchiectasis has a PDUFA target action date of August 12, 2025; Insmed expects an immediate U.S. launch if approved
- TPIP Phase 2b PAH study met its primary endpoint with statistically significant placebo-adjusted reductions in pulmonary vascular resistance; Phase 3 in PH-ILD planned for 2H 2025
- Reiterated full-year 2025 global ARIKAYCE revenue guidance of $405 million to $425 million
- Cash, cash equivalents, and marketable securities of approximately $1.9 billion as of June 30, 2025, after a June 2025 equity offering with estimated net proceeds of $823.1 million
- Redeemed all $569.5 million of remaining 0.75% convertible senior notes due 2028 in April 2025
03—Questions
Frequently Asked Questions
When is the FDA decision expected for brensocatib, and what happens if it is approved?
The PDUFA target action date for brensocatib in bronchiectasis is August 12, 2025. The filing states that if approved, Insmed expects to immediately launch brensocatib in the U.S. Regulatory submissions in Europe and the UK have been accepted, with commercial launches anticipated in 2026 pending approval.
How did ARIKAYCE perform in the second quarter of 2025?
Global ARIKAYCE revenue was $107.4 million for Q2 2025, up 18.9% from $90.3 million in Q2 2024. U.S. revenue was $68.7 million (up 7.7%), Japan was $30.7 million (up 45.3%), and Europe & Rest of World was $8.1 million (up 48.3%).
What drove the increase in operating expenses?
R&D expenses rose to $177.2 million from $146.7 million, mainly due to higher manufacturing expenses, compensation, and stock-based compensation from increased headcount. SG&A rose to $154.8 million from $106.6 million, reflecting headcount growth and professional fees tied to commercial readiness for brensocatib.
What is the company's cash position and how is it funded?
As of June 30, 2025, Insmed had approximately $1.9 billion in cash, cash equivalents, and marketable securities. The June 2025 public offering of 8,984,375 shares, including the full exercise of the underwriters' option, generated estimated net proceeds of $823.1 million.
What are the upcoming pipeline milestones?
Insmed expects topline data from the Phase 2b BiRCh study of brensocatib in CRSsNP by the end of 2025 and an interim futility analysis for the Phase 2b CEDAR study in HS in the first quarter of 2026. TPIP Phase 3 studies are planned for PH-ILD in the second half of 2025 and PAH in early 2026. The ENCORE Phase 3 readout for ARIKAYCE is anticipated in the first half of 2026.
04—Continue